On March 30, 2026, Sight Sciences, Inc. announced a significant legal victory in its patent infringement case against Alcon Inc. The U.S. District Court for the District of Delaware upheld the jury's verdict of willful infringement regarding three patents held by Sight Sciences, specifically related to Alcon's Hydrus® Microstent. The court awarded Sight Sciences $34 million in monetary damages, which includes $5.5 million in lost profits and $28.5 million in royalty damages for Hydrus sales from its commercial launch through the jury verdict. Additionally, the court ordered an ongoing royalty of 10% on Hydrus revenue until the expiration of the last asserted patent on November 10, 2028. This ruling is expected to have a substantial positive impact on Sight Sciences' financial outlook, as it not only validates the company's intellectual property but also provides a significant revenue stream through ongoing royalties. The final judgment is anticipated to be entered in the coming months, subject to potential appeals by Alcon. Sight Sciences has expressed confidence in its strong intellectual property portfolio and its commitment to advancing glaucoma care through innovative technologies. The company is represented by Cooley LLP in this litigation, and it expects to incur a $5.4 million success fee related to this case, which will be excluded from its non-GAAP adjusted operating expenses. This legal victory positions Sight Sciences favorably in the competitive eyecare technology market, reinforcing its strategy to safeguard its innovations and continue investing in future developments.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.